Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galiximab

Next Previous
X
Search
Drug Profile

Galiximab

Alternative Names: IDEC 114; IDEC 114-20

Latest Information Update: 23 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD80 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Autoimmune disorders; Non-Hodgkin's lymphoma; Psoriasis

Most Recent Events

  • 04 Feb 2011 Galiximab is available for licensing as of 04 Feb 2011. www.biogenidec.com
  • 09 Dec 2008 Efficacy and adverse events data from a long-term follow up of a phase II trial in Non-Hodgkin's lymphoma presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
  • 30 Jan 2007 Discontinued - Phase-II for Autoimmune disorders in USA (Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top